These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 11286313)

  • 1. Glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins: a combined role in coronary interventions?
    Fry ET
    Clin Cardiol; 2001 Mar; 24(3 Suppl):I8-11. PubMed ID: 11286313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
    Bosanquet N; Jönsson B; Fox KA
    Pharmacoeconomics; 2003; 21(16):1135-52. PubMed ID: 14594436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
    Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
    Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparins combined with platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.
    Salam AM
    Expert Opin Investig Drugs; 2003 Sep; 12(9):1567-70. PubMed ID: 12943500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.
    Singh KP; Roe MT; Peterson ED; Chen AY; Mahaffey KW; Goodman SG; Harrington RA; Smith SC; Gibler WB; Ohman EM; Pollack CV;
    J Thromb Thrombolysis; 2006 Jun; 21(3):211-20. PubMed ID: 16683212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of combined low molecular weight heparin and glycoprotein IIb/IIIa inhibitors.
    Kovar D; Canto JG; Rogers WJ
    Am J Cardiol; 2002 Nov; 90(9):911-5. PubMed ID: 12398953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparins for the treatment of acute coronary syndromes.
    Wong GC; Giugliano RP
    Semin Vasc Med; 2003 Nov; 3(4):391-402. PubMed ID: 15199446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.
    Cho JS; Her SH; Baek JY; Park MW; Kim HD; Jeong MH; Ahn Yk; Chae SC; Hur SH; Hong TJ; Kim YJ; Seong IW; Chae JK; Rhew JY; Chae IH; Cho MC; Bae JH; Rha SW; Kim CJ; Choi D; Jang YS; Yoon J; Chung WS; Cho JG; Seung KB; Park SJ;
    J Korean Med Sci; 2010 Nov; 25(11):1601-8. PubMed ID: 21060749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention.
    Wong GC; Giugliano RP; Antman EM
    JAMA; 2003 Jan; 289(3):331-42. PubMed ID: 12525234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
    Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
    J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on Enoxaparin.
    Ferguson JJ
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E10-3;discussion E25-8. PubMed ID: 11156723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary intervention.
    Huston SA; Hawkins D
    Curr Pharm Des; 2008; 14(12):1197-204. PubMed ID: 18473867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
    J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-molecular-weight heparins and glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
    Ferguson J
    J Invasive Cardiol; 2004 Mar; 16(3):136-44. PubMed ID: 15152164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.